PSC
ADMA icon

Piper Sandler & Co’s ADMA Biologics ADMA Stock Holding History

Piper Sandler & Co’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-46
Closed – – 31
2015
Q3 		$0 Buy
+46
New +$425 ﹤0.01% 106

Other funds holding ADMA

AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
WMSA
Weiss Multi-Strategy Advisers New York $4.16B AUM 30.77% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Piper Sandler & Co's ADMA Position: Q4 2015 in Review

Piper Sandler & Co sold out of ADMA Biologics (ADMA) in Q4 2015, closing a stake of 46 shares.

Piper Sandler & Co first reported a position in ADMA in Q3 2015 and held it in 1 quarter. The position peaked at $0 in Q3 2015. 26 funds tracked by Wall St. Rank hold ADMA as of Q4 2015.

  • Piper Sandler & Co reported no remaining ADMA Biologics position as of Q4 2015 after selling out during the quarter.
  • Piper Sandler & Co sold 46 ADMA Biologics shares in Q4 2015.
  • Piper Sandler & Co first reported a position in ADMA Biologics in Q3 2015 and held it in 1 quarter.
  • Piper Sandler & Co's ADMA Biologics position peaked at $0 in Q3 2015.
  • 26 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2015.

Based on Piper Sandler & Co's 13F filing for Q4 2015, filed 16 Feb 2016.